Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement—A new target for lupus treatment by Smith, Nikaïa et al.
HAL Id: pasteur-02282952
https://hal-pasteur.archives-ouvertes.fr/pasteur-02282952
Submitted on 10 Sep 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Distributed under a Creative Commons Attribution - NonCommercial| 4.0 International
License
Control of TLR7-mediated type I IFN signaling in pDCs
through CXCR4 engagement-A new target for lupus
treatment
Nikaïa Smith, Mathieu Rodéro, Nassima Bekaddour, Vincent Bondet, Yasser
Ruiz-Blanco, Mirja Harms, Benjamin Mayer, Brigitte Badder-Meunier, Pierre
Quartier, Christine Bodemer, et al.
To cite this version:
Nikaïa Smith, Mathieu Rodéro, Nassima Bekaddour, Vincent Bondet, Yasser Ruiz-Blanco, et al..
Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement-A new target for
lupus treatment. Science Advances , American Association for the Advancement of Science (AAAS),
2019, 5 (7), pp.eaav9019. ￿10.1126/sciadv.aav9019￿. ￿pasteur-02282952￿
Smith et al., Sci. Adv. 2019; 5 : eaav9019     10 July 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
1 of 14
I M M U N O L O G Y
Control of TLR7-mediated type I IFN signaling in pDCs 
through CXCR4 engagement—A new target for  
lupus treatment
Nikaïa Smith1,2,3,4*, Mathieu P. Rodero1,2,3, Nassima Bekaddour1,2,3, Vincent Bondet5,6,  
Yasser B. Ruiz-Blanco7, Mirja Harms4, Benjamin Mayer8, Brigitte Bader-Meunier3,9,10,11, 
Pierre Quartier3,9,10, Christine Bodemer3,9,12, Véronique Baudouin13, Yannick Dieudonné14,15,16, 
Frank Kirchhoff4, Elsa Sanchez Garcia7, Bruno Charbit17, Nicolas Leboulanger3,18, 
Bernd Jahrsdörfer19, Yolande Richard3,20,21, Anne-Sophie Korganow14,15,16, Jan Münch4, 
Sébastien Nisole22, Darragh Duffy5,6,17, Jean-Philippe Herbeuval1,2,3*
Type I interferons are highly potent cytokines essential for self-protection against tumors and infections. Deregu-
lations of type I interferon signaling are associated with multiple diseases that require novel therapeutic options. 
Here, we identified the small molecule, IT1t, a previously described CXCR4 ligand, as a highly potent inhibitor of 
Toll-like receptor 7 (TLR7)–mediated inflammation. IT1t inhibits chemical (R848) and natural (HIV) TLR7-mediated 
inflammation in purified human plasmacytoid dendritic cells from blood and human tonsils. In a TLR7-dependent 
lupus-like model, in vivo treatment of mice with IT1t drives drastic reduction of both systemic inflammation and 
anti–double-stranded DNA autoantibodies and prevents glomerulonephritis. Furthermore, IT1t controls inflammation, 
including interferon  secretion, in resting and stimulated cells from patients with systemic lupus erythematosus. 
Our findings highlight a groundbreaking immunoregulatory property of CXCR4 signaling that opens new thera-
peutic perspectives in inflammatory settings and autoimmune diseases.
INTRODUCTION
Type I interferons (IFNs) are key immune response mediators and, 
in humans, are composed of 13 IFN- subtypes as well as IFN-, 
IFN-, IFN-, and IFN-. Type I IFNs signal through a ubiquitously 
expressed common receptor (IFNAR) formed by two transmembrane 
proteins, IFNAR1 and IFNAR2. IFNAR engagement results in acti-
vation of the cytoplasmic kinases Janus kinase 1 (JAK1) and tyrosine 
kinase 2 (TYK2), leading to the formation of the transcription factor 
complex IFN-stimulated gene factor 3 (ISGF3). This complex trans-
locates to the nucleus to promote transcription of IFN-stimulated genes 
(ISGs) (1). Type I IFNs exert antiproliferative and immunomodulatory 
effects, essential to control viral infection and spread. However, sus-
tained overproduction of type I IFN can be deleterious for the host in 
various infection settings (2) and in a class of disorders collectively 
termed type I interferonopathies (3) composed of rare monogenic 
diseases and complex inflammatory/autoimmune diseases such as 
systemic lupus erythematosus (SLE).
The recurrent development of lupus-like symptoms in patients 
receiving recombinant type I IFN for treatment of hepatitis or hem-
atological disorders highlights the frequent pathogenic effects of 
these molecules in individuals with susceptibility to autoimmune 
disorders. SLE is a heterogeneous disease at the clinical and molecular 
level, with at least seven subtypes identified by blood transcriptome 
profile in pediatric SLE (4). However, all subtypes present the common 
feature of increased IFN signaling. Moreover, we previously demonstrated 
that increased IFN- levels in the serum of patients with SLE correlate 
with both disease activity [SLE disease activity index (SLEDAI)] and 
the expression of prognostic markers such as anti–double- stranded 
DNA (dsDNA) antibodies and complement activity (5).
Plasmacytoid dendritic cells (pDCs) are specialized in rapid and 
massive secretion of type I IFN (6–8). pDCs are activated after recog-
nition of pathogen nucleic acids by sensors such as Toll-like receptors 
(TLRs). pDCs express TLR7 and TLR9 (9, 10), which respond to single- 
stranded RNA (ssRNA) and imidazoquinolines (R848) (11, 12) or 
DNA and CpG-containing oligonucleotides (13), respectively. TLR 
activation triggers production of type I IFN and proinflammatory 
cytokines through MyD88-mediated IRF7 signaling (14). Many 
studies have highlighted a central implication of pDCs in the develop-
ment of SLE, making these cells paramount targets for innovative 
therapies (15). This is further supported by an up- regulation of 
TLR7-mediated IFN- production by pDCs in patients with SLE (16). 
Despite evaluations of multiple therapeutic strategies including 
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anti-IFN and anti-IFNAR antibodies, a drug specifically targeting 
the type I IFN pathway in SLE fails to demonstrate efficacy. Molec-
ular heterogeneity of SLE may provide an explanation for the failure 
of clinical trials based only on clinical diagnosis (1).
Previous studies have proposed the chemokine receptor CXCR4 as 
a promising drug target to reduce SLE symptoms in severe pathology 
through inhibition of inflammatory cell recruitment (17, 18). Consis-
tently, we recently discovered that binding of small natural and synthetic 
amino compounds to CXCR4 drives a profound immunosuppressive 
signaling in human pDCs (19). However, none of these amino com-
pounds were highly specific for CXCR4. Therefore, we aimed to assess 
two specific ligands with high affinity for CXCR4: the small amino 
compound named IT1t that was identified as a potential candidate as it 
is the only small molecule that cocrystalized with CXCR4 (20) and the 
AMD3100 (Plerixafor), a Food and Drug Administration (FDA)– 
approved CXCR4 blocker used for CD34+ bone marrow–derived pro-
genitor cell collection before hematopoietic stem cell transplantation 
(21). IT1t and AMD3100 bind differently to CXCR4 into the major or 
the minor subpocket of CXCR4, respectively (20, 22), which are also 
different from CXCL12 (CXCR4 natural ligand) binding sites.
We examined the effects of IT1t and AMD3100 on pDC activa-
tion and IFN production. Notably, we found that IT1t, but not 
AMD3100, strongly inhibits TLR7–type I IFN signaling in human 
pDCs from blood and tonsils. Moreover, IT1t controls inflamma-
tion in cells of patients with lupus and drastically reduced inflam-
mation and levels of dsDNA antibodies, a pathogenesis marker, in a 
pristane-induced SLE mouse model. Our study identifies the IT1t 
binding site on CXCR4 as a potential modulator of pDC activity 
and places this pocket as a promising novel therapeutic target in 
autoimmune diseases.
RESULTS
IT1t controls TLR7-mediated type I IFN signaling in human 
pDCs in a CXCR4-dependent manner
We previously demonstrated that engagement of CXCR4 by natural 
amines and the synthetic mimic of histamine (clobenpropit) strongly 
inhibits viral-induced inflammation of human primary pDCs (19). 
To identify synthetic compounds with similar properties, we searched 
for known CXCR4 ligands with similar structures. The first cocrys-
talized structure of CXCR4 was achieved with a small compound 
called IT1t showing a strong structural homology with clobenpropit 
(fig. S1, A to C) (20). IT1t binds to an allosteric deep pocket that 
appears to be distinct from the FDA-approved CXCR4 antagonist 
AMD3100 binding site (fig. S1, D and E) (23, 24). These pockets 
were called major pocket for the AMD3100 binding site (fig. S1F) 
and minor subpocket for the IT1t binding site (fig. S1G) (20, 22), 
opening the possibility for distinct biological activity. Furthermore, 
IT1t Ki was evaluated previously and had a value of 0.41 ± 0.07 nM (19).
Given the central role of TLR7-driven type I IFN production in 
the pathophysiology of SLE, we investigated the ability of IT1t to 
control secretion of type I IFN by pDCs activated by distinct TLR7 
agonists (R848 and HIV-1). A dose range from 0 to 50 M AMD3100 
and IT1t was added to pDCs in vitro in the presence or absence of 
R848 overnight. We first tested the potential cytotoxicity of both 
molecules on purified human pDCs (fig. S1H) activated by the 
TLR7/TLR8 synthetic stimulator R848 by flow cytometry and showed 
that neither IT1t nor AMD3100 induced toxicity up to 50 M (fig. S1, 
I to M). R848 induced a massive increase of intracellular IFN- pro-
duction in purified pDCs (Fig. 1A). This increase was blocked in a 
dose-dependent manner by IT1t starting from 5 M. In contrast, 
AMD3100 did not display any inhibitory activity as we previously 
reported (19). To verify the efficacy of AMD3100, we tested it on 
HIV-1 infection, and we confirmed that both AMD3100 and IT1t 
were able to block HIV-1 X4 tropism infection but not HIV-1 R5 
tropism as previously demonstrated (fig. S1, N and O) (25, 26). 
IT1t-specific inhibition of R848-induced IFN- production in pDCs 
was confirmed with cells derived from six individual donors 
(Fig. 1, B and C). In agreement with a reduced intracellular expres-
sion of IFN, IT1t treatment also resulted in greatly reduced IFN-/ 
protein concentrations in supernatants of R848-stimulated pDCs 
(Fig. 1D). To confirm the ability of IT1t to control TLR7-induced 
IFN-, we evaluated its efficacy after HIV-1 stimulation, also known 
to be a strong TLR7 activator (12). As previously published (19), 
we did not observe any inhibitory activity of AMD3100. However, 
IT1t significantly reduced virus-induced IFN- production at con-
centrations ≥5 M (fig. S2, A to E). To further address the mechanism 
associated with IT1t inhibition of type I IFN in primary pDCs, we 
performed intracellular IFN- and pIRF7 staining on R848-stimulated 
cells in the presence or absence of IT1t (Fig. 1, E and F). As expected, 
R848 treatment is associated with a strong increase of pIRF7+ pDCs. 
Furthermore, 50% of the pIRF7+ cells coexpressed IFN-. Under IT1t 
treatment, pDCs failed to phosphorylate IRF7 and, consequently, 
did not express IFN-. Furthermore, we showed by confocal micros-
copy that pIRF7 translocates into the nucleus of cells upon R848 
activation (Fig. 1G), which was in turn inhibited by IT1t treatment 
(Fig. 1H). We validated the latest results by real-time quantitative 
polymerase chain reaction (RT-qPCR) and showed reduced levels 
of total IRF7 messenger RNA (mRNA) (Fig. 1G).
To definitively demonstrate that the IT1t immunoregulatory effect 
is dependent on CXCR4, we silenced CXCR4 expression using a 
previously established small interfering RNA (siRNA) protocol in 
human pDCs (27). We first confirmed the efficiency of our silencing 
by measuring CXCR4 mRNA expression by RT-qPCR (Fig. S3A). 
TLR7 stimulation by HIV particles strongly induced type I IFN and 
ISG (TRAIL or TNF-related apoptosis-inducing ligand) transcrip-
tions, which were potently inhibited by IT1t. As expected, IT1t in-
hibitory effect on TLR7-mediated type I IFN and ISG transcription 
was almost abrogated in siCXCR4 but not in control siRNA cyclo-
philin B (siCTR)–treated cells (fig. S3, B and C).
To obtain more comprehensive insights into the effect of IT1t on 
pDC activation, we performed a gene expression array of 579 in-
flammatory markers in R848-stimulated pDCs from three donors 
treated or not with IT1t. Principal components analysis (PCA) showed 
that cells from each donor clustered together depending on treatment 
(Fig. 2A). Of the 579 genes analyzed, 136 significantly increased 
(n = 68) or decreased (n = 70) under R848 stimulation (Fig. 2B). 
Expectedly, 53% of the 68 genes up-regulated are IFN genes (n = 3) 
and ISGs (n = 32) (Fig. 2C). In comparison, pDCs stimulated with 
R848 and treated with IT1t display significant up-regulation of merely 
18 genes (8 ISGs, 10 IFN). We further confirmed our results on 
selected genes by RT-qPCR on two different donors and showed 
that type I IFN, TRAIL, and MxA were inhibited in R848-stimulated 
pDCs by IT1t (Fig. 2D). Note that genes up- regulated by R848 treat-
ment do not reflect the proportion of the different class of genes in 
the array. Notably, ISGs increased from 24% in the whole array to 
48% in the R848-induced gene list, supporting the impact of this 
stimulation on type I IFN signaling (fig. S4).
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Fig. 1. IT1t suppresses TLR7-mediated IFN- production in pDCs. Isolated human pDCs were preincubated with IT1t or AMD3100 and then stimulated with R848 
overnight (5 g/ml). (A) pDCs were cultured with R848 in the presence of increased dose of AMD3100 or IT1t. Intracellular levels of IFN- were evaluated by flow cytometry. 
SSC-A, side scatter. (B) Individual and (C) combined representation of the effect of AMD3100 and IT1t on the IFN- production of R848-stimulated pDCs from six healthy 
donors. Box and whisker plots with median ± minimum to maximum. Friedman test with Dunn’s post hoc correction. “*” represents the statistical analysis comparing IT1t 
to the control R848 alone. “X” represents the statistical analysis comparing each concentration of IT1t to AMD3100. (D) Cytokine production was measured in the super-
natant of the cells from six healthy donors using the multiplex bead-based immunoassay LEGENDplex. Average baseline of the nonstimulated condition is represented 
by the red dashed line. Wilcoxon test. (E) Intracellular levels of phosphorylated IRF7 and IFN- were evaluated by flow cytometry. (F) Quantification of pIRF7 from seven 
individuals obtained by flow cytometry. Box and whisker plots with median ± minimum to maximum. Kruskal-Wallis with Dunn’s post hoc correction. (G) Quantification 
by microscopy of the number of pIRF7+ pDCs out of 130 cells per condition in average. Friedman test with Dunn’s post hoc correction. (H) Confocal microscopy of purified 
pDCs showing pIRF7 (green) and nucleus [DAPI (4′,6-diamidino-2-phenylindole), blue]. Scale bars, 5 m. 3D was reconstructed with ImageJ using, on average, 30 stacks. 
(I) mRNA levels of IRF7 were quantified by RT-qPCR. ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05. NS, nonstimulated.
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Fig. 2. IT1t prevents TLR7-mediated inflammation in pDCs. Isolated human pDCs were cultured with R848 (5 g/ml) in the presence or absence of IT1t (20 M). 
Total RNA from the cells was isolated and analyzed using the NanoString nCounter. (A) PCA was performed on the basis of 136 genes from the array differentially ex-
pressed between the NS (gray) and the R848 (orange) conditions. (P < 0.05, fold change > 2). (B) Heat map represents mRNA fold increase of the 136 genes significantly 
differently expressed between the NS and the R848 condition (P < 0.05, fold change > 2). (C) Pie chart representation of the promoters associated with genes signifi-
cantly up-regulated between the NS and the stimulated (R848) condition and between the NS and the R848 + IT1t condition (P < 0.05, fold change > 2). The red parts 
represent ISGs (ISGF3 promoter) and the type I IFN (IRF7 promoter). Areas of the pie slices are representative of the number of genes. (D) mRNA levels of various 
genes were quantified by RT-qPCR for confirmation in two healthy donors. (E) Heat map represents the mRNA fold increase of 85 genes differently expressed 
between the NS (gray) and the IT1t (green) condition (P < 0.05, fold change > 2.5). (F) Pie chart represents the impact on inflammation of differently expressed 
genes between NS and IT1t. NS, nonstimulated.
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The comparison of gene expression levels between the nonstimu-
lated and the IT1t groups reveals that IT1t modulates gene transcription 
in the absence of stimulation (Fig. 2E). We identified 23 up-regulated 
and 62 down-regulated genes in pDCs treated with IT1t compared 
to the nonstimulated condition (fold change > 2.5; P < 0.05). IT1t 
treatment alone induced an enrichment of proinflammatory genes 
in the most down-regulated genes and an enrichment of anti- 
inflammatory genes, including SOCS1, SOCS3, and IRF4 in the 
most up-regulated genes (Fig. 2F). Together, these results demon-
strate that IT1t treatment controls TLR7-induced type I IFN signaling 
in human pDCs at the transcriptomic and proteomic level in a CXCR4- 
dependent manner.
IT1t controls TLR7-mediated type I IFN and inflammation in 
mixed cell populations
As pDCs represent a very small fraction of immune cells in circula-
tion (0.1 to 0.8%), we aimed to address whether we could target this 
rare population in the peripheral blood mononuclear cells (PBMCs). 
First, we assessed which leukocyte subsets in PBMCs could produce 
IFN- upon R848 stimulation. R848 did not induce IFN- produc-
tion in CD3+ T cells, CD56+ NK (natural killer) cells, CD3+CD56+ 
NK T cells, CD19+ B cells, or CD14+ monocytes (Fig. 3A). However, a 
strong increase of IFN-+ pDCs was observed after stimulation. Overall, 
more than 90% of the IFN-–producing cells were CD123+BDCA4+ 
pDCs (Fig. 3, B and C). Furthermore, treatment of PBMCs with 
IT1t reduced IFN- production by pDCs in a dose-dependent manner 
(Fig. 3, D and E).
Human tonsils represent an integrative and physiological ex vivo 
model to study innate immune responses at the mucosal interface 
(Fig. 4A) (28, 29). We thus tested IT1t biological activity on tonsil 
mononuclear cell suspensions (TMCs), which mimic the role of a 
secondary lymphoid organ. We first characterized the immune pro-
file of cells present in the culture and quantified the number of 
pDCs, which represents about 5% of the lineage-negative HLA-DR– 
positive (Lin−DR+) immune cells (Fig. 4, B and C). Stimulation of 
TMCs overnight with R848 increased the frequency of IFN-+ pDCs 
about 10-fold, and treatment with IT1t (20 M) resulted in a 67% 
reduction of this induction (Fig. 4D). We thus took advantage of the 
cellular diversity of the TMC model to evaluate the impact of IT1t 
on a broader set of inflammatory molecules. TMCs from seven do-
nors were stimulated with R848 in the presence or absence of IT1t. 
IT1t reduced type I and type II IFN, proinflammatory cytokines [IL-6 
(interleukin-6), TNF- (tumor necrosis factor–), IL-1, IL-12p70, 
and GM-CSF (granulocyte-macrophage colony-stimulating factor)], 
Fig. 3. IT1t blocks TLR7-mediated IFN production of circulating pDCs in PBMC cultures. (A and B) PBMCs from healthy individuals were cultured with R848 (5 g/ml). 
IFN-producing cells were identified by flow cytometry. (C) Percentage of pDCs within the IFN-+ PBMCs after R848 stimulation from six different donors. (D) Individual and 
(E) combined representation of the effects of AMD3100 and IT1t on R848-induced IFN- production in the pDC fraction from PBMCs from four healthy donors. Box and 
whisker plots with median ± minimum to maximum. Friedman test with Dunn’s post hoc correction. “*” represents the statistical analysis comparing IT1t to the control 
R848 alone. “X” represents the statistical analysis comparing each concentration of IT1t to AMD3100. **P < 0.01, *P < 0.05. NS, nonstimulated.
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and chemokine (CXCL-10) protein production in cells from all seven 
donors (Fig. 4, E and F). Therefore, IT1t controls type I IFN and a 
large spectrum of inflammatory cytokine production in isolated 
pDCs, as well as in complex cell populations.
IT1t suppresses inflammation and disease progression in an 
SLE mouse model
We next aimed to evaluate whether IT1t-mediated immune modu-
lation could have an impact in inflammatory disease progression. 
SLE represents one of the most common interferonopathies (30). 
TLR7 and TLR7-mediated IFN signaling are well documented as a 
major player of SLE disease development (16, 31–33) and response 
to treatment (34). Several mouse models have led to a clearer under-
standing of the role of type I IFN in the pathogenesis of lupus-like 
disease. Nevertheless, pristane-induced SLE meets most of the Systemic 
Lupus Erythematosus International Collaborating Clinics (SLICC) 
criteria used for human lupus classification, with the presence of 
an IFN signature and anti-dsDNA antibodies (35). Pristane induces 
type I IFN production mainly through the TLR7/MyD88 pathway 
(36). TLR7 deficiency not only abolishes pristane-induced type I 
IFN production but also prevents autoantibody production and renal 
disease, indicating a key role of TLR7/MyD88/type I IFN pathway 
in this model (36, 37). Given the broad immunoregulatory proper-
ties of IT1t under TRL7 stimulation, including inhibition of type I 
and type III IFNs, TNF-, and IL-6 protein production, we evaluated 
the effect of IT1t as a valuable therapeutic approach for SLE.
First, by using either a system of reporter cell line measuring all 
types of IFN (STING-37 cells) (38) or a specific IFN- bead assay 
(LEGENDplex), we showed that in ex vivo tonsil cultures, pristane 
induced IFN- production, which was significantly reduced by IT1t 
treatment (Fig. 5, A and B). Then, SLE was induced in BALB/c mice 
by daily intraperitoneal coinjection of pristane (0.5 ml per mouse) 
with vehicle or with different IT1t doses (3, 10, and 30 mg/kg or mpK) 
for 10 weeks. As a reference treatment, SLE mice were treated daily 
with the corticosteroid prednisolone at 15 mpK (Fig. 5C). IT1t-treated 
mice did not demonstrate any sign of stress or weight loss as com-
pared to vehicle, indicating the good tolerance of the treatment by 
the animals (Fig. 5D).
Cytokines IFN-, IL-1, IL-17, TNF-, and TRAIL were quanti-
fied as markers for SLE from serum at weeks 4 and 10. It should be 
noted that IFN- was not detectable in serum of pristane-treated 
mice. However, we could detect increased levels of the IFN-induced 
protein TRAIL and of inflammatory cytokines. Prednisolone treat-
ment was used as a positive therapeutic control and reduced all cy-
tokines measured (Fig. 5, E to H). IT1t, similarly to prednisolone, 
strongly reduced production of IL-1, IL-17, and TRAIL in a dose- 
dependent manner (Fig. 5, E to H). The production of TNF- at 
week 10 was totally inhibited by prednisolone in contrast to IT1t 
treatments (Fig. 5G). Thus, these results suggest a distinct pattern of 
immunosuppressive activity of prednisolone and IT1t in SLE mice. 
The severity of SLE pathogenesis was also estimated by measuring 
levels of dsDNA antibodies. The high dose of IT1t significantly de-
creased anti-dsDNA levels during the whole treatment as early as 
week 4, in contrast to prednisolone, which only significantly re-
duced antibodies levels at week 8 (Fig. 5I). In line with this observation, 
we observed a reduced proportion of mice developing glomerulo-
nephritis in the groups treated with 10 and 30 mpK of IT1t com-
pared to vehicle (Fig. 5J). Together, these results highlight that 
intraperitoneal injection of IT1t reduces SLE-associated phenotypes 
faster than the reference corticosteroid treatment and with a greater 
selectivity on cytokine production.
IT1t controls type I IFN in vitro in cells from patients with SLE
SLE is a chronic disease characterized by periods of low disease 
activity and periods of high disease activity termed “flares,” where 
patients experience an inflammatory storm associated with fever 
and skin rash (39). We recently demonstrated that circulating levels 
of IFN- are higher in SLE patients with greater disease activity (5). 
Therefore, we evaluated whether IT1t treatment reduces TLR7- 
mediated IFN- production in these patients. PBMCs from healthy 
controls and patients with lupus were stimulated with R848 to mimic 
an inflammatory burst with a strong type I IFN signature (Fig. 6A). 
Fig. 4. IT1t suppresses TLR7-mediated inflammation in tonsil resident pDCs. (A) 
Picture of human tonsil after surgical removal. (B) pDCs from tonsils were identified as 
CD8-CD3-CD16-CD14-CD123 + HLADR+BDCA-4+. (C) Percentage of pDCs within the 
Lin−DR+ cells from eight human tonsils. (D) TMCs of healthy individuals were cultured 
with R848 (5 g/ml) in the presence or absence of IT1t (20 M). IFN+ pDCs were identi-
fied and quantified by flow cytometry. (E and F) Effect of IT1t on R848-stimualted TMCs 
was evaluated in the supernatant of seven healthy individuals using LEGENDplex. (E) 
Heat map represents the fold increase in cytokine secretion compared to NS. “*” 
represents the statistical analysis comparing the R848 to the NS condition. “X” represents 
the statistical analysis comparing the R848 to the R848 + IT1t condition. (F) Graphs 
represent the concentration in picograms per milliliter of each measured cytokine. Box and 
whisker plots with median ± minimum to maximum. Friedman test with Dunn’s post 
hoc correction. *** or XXXP < 0.001, ** or XXP < 0.01, * or XP < 0.05. (Photo credit: N. Smith, 
CNRS UMR-8601, CBMIT, Université Paris Descartes, Paris, France, and Institute of 
Molecular Virology, Ulm University Medical Center, Ulm, Germany.) NS, nonstimulated.
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IT1t treatment controlled IFN production in patients’ and controls’ 
PBMCs (Fig. 6B). Intracellular flow cytometry analysis reveals that 
R848-induced IFN production by patient and control PBMCs was 
mainly restricted to pDCs, which is in line with our previous obser-
vations. Furthermore, this IFN production by pDCs was abrogated 
by IT1t treatment (Fig. 6, C and D).
In humans, SLE is known to be a very heterogeneous disease with 
a large phenotypic and inflammatory spectrum (40). This heterogeneity 
Fig. 5. IT1t reduces TLR7-mediated inflammation and markers of disease progression in SLE mice. Human TMCs were preincubated with IT1t or AMD3100 (20 M) 
and stimulated overnight with pristane (200 g/ml). IFN production was measured in supernatants using (A) the STING-37 reporter cell line or (B) the multiplex bead-
based immunoassay LEGENDplex. Box and whisker plots with median ± minimum to maximum. Kruskal-Wallis test with Dunn’s post hoc correction. (C) Mice were injected 
intraperitoneally daily with 0.5 ml of pristane to induce disease and with treatment consisting of prednisolone (15 mg/kg) or 3, 10, or 30 mpK of IT1t for 10 weeks. (D) Body weight 
was measured. (E to H) Inflammatory status was evaluated in the serum of mice by protein dosage of IL-1 (E), IL-17 (F), TNF- (G), and TRAIL (H). Two-way repeated- 
measures analysis of variance (RM ANOVA) with Bonferroni post hoc correction. One-way ANOVA for TRAIL. (I) Anti-dsDNA antibody titers were measured on weeks 4, 8, 
and 10. Two-way RM ANOVA with Bonferroni post hoc correction. (J) Relative proportion of mice that develop glomerulonephritis in each group compared to the vehicle 
was assessed. All data are presented as mean ± SEM. ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05. n = 8 mice per group. NS, nonstimulated.
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was observed in cultured PBMCs from patients, with some demon-
strating a measurable spontaneous inflammation (SpI patients), 
while being undetectable in others. To assess the capacity of IT1t to 
control human lupus–driven spontaneous inflammation, we cul-
tured PBMCs of four patients and monitored IFN- secretion by 
digital ELISA (enzyme-linked immunosorbent assay), STAT1 (signal 
transducer and activator of transcription 1) and STAT3 phos-
phorylation status by flow cytometry, and inflammatory transcript 
levels by RT-PCR (Fig. 6E). For all patients with constitutive in 
vitro secretion of IFN-, we observed a strong inhibition with IT1t 
treatment (Fig. 6F). Similarly, in cells from patients with sponta-
neous up-regulation of pSTAT1 and pSTAT3, IT1t treatment was 
associated with a reduction of STAT1 and STAT3 phosphorylation 
to a level similar to cells from healthy individuals (Fig. 6, G to J). 
Despite heterogeneous inflammatory profiles, treatment with IT1t 
consistently normalized the level of inflammatory gene transcripts 
in cells from patients with lupus (Fig. 6K), suggesting that targeting 
of CXCR4 by IT1t constitutes a promising strategy for controlling 
human inflammation.
DISCUSSION
New strategies to block the type I IFN pathway in SLE pathology are 
of great interest. In this study, we show that IT1t, a CXCR4 minor 
pocket ligand, has a strong immunosuppressive activity on TLR7- 
activated pDCs. Furthermore, IT1t treatment controlled inflamma-
tion, reduced dsDNA antibody titers in a lupus mouse model, and 
controlled type I IFN production and signaling in cells isolated 
from patients with lupus. We propose to consider targeting CXCR4 
using small amino compounds such as IT1t as a potential innovative 
therapeutic strategy in interferonopathies.
pDCs are specialized in rapid and massive secretion of type I 
IFN in response to innate immune sensor stimulation from the TLR 
family (8, 10, 41, 42). There is supporting evidence that overproduc-
tion of type I IFN by pDCs is central in development and progres-
sion of numerous inflammatory diseases (43, 44). Thus, we aimed 
to specifically target pDC activation. We previously showed that 
clobenpropit (CB), an antihistamine, modulates pDC activation by 
engagement of CXCR4 (19). Therefore, as pDCs express high levels 
of CXCR4, we hypothesized that pDC activation could be specifi-
cally targeted with small amino compounds interacting with this 
chemokine receptor. However, given the large expression profile of 
histamine receptors, it is challenging to predict the mechanism of 
action in a mixed cell population or in a small animal model. We 
identified IT1t as a compound with similar immunoregulatory 
properties to histamine and with a high specificity toward CXCR4. 
We demonstrated that IT1t but not AMD3100, a clinically used 
CXCR4 antagonist, exhibits strong inhibitory activity on type I IFN 
production by TLR7-activated primary pDCs. Notably, both syn-
thetic ligand (R848) and viral (HIV) activation of pDCs were 
strongly inhibited by IT1t but not by AMD3100. This raises the 
ability of amino compounds targeting CXCR4 to be considered as 
therapeutic strategies in both inflammatory and chronic infectious 
diseases, where sustained production of type I IFN is thought to 
impair the immune response (45–47).
It is clear that IT1t inhibitory activity on isolated primary pDCs 
was fully dependent on CXCR4 engagement as demonstrated by the 
loss of the IT1t effect in CXCR4 siRNA-treated cells. The IFN- pro-
duced following R848 stimulation in human TMCs and PBMCs 
from healthy controls and patients with SLE was mostly due to 
pDCs. Together, our in vitro data validate IT1t as a potent inhibitor 
of type I IFN production by activated pDCs.
Targeting type I IFN production and proinflammatory cytokines 
in chronic diseases is the predominant therapeutic option in SLE 
(48). However, despite the identification of the up-regulation of IFN 
signaling in SLE decades ago (49, 50), anti-IFN therapies have de-
veloped slowly owing to the heterogeneity of SLE disease progression 
(48) and have yet to reach routine clinical practice. Antibody- based 
IFN therapies have not yet progressed beyond phase 2 develop-
ment, while the more promising anti-IFNAR approach (51) recently 
failed to achieve the primary end point in a phase 3 clinical study. 
Specific targeting of pDCs has provided promising results (52), 
leading to clinical trials based on anti-BDCA2 and anti-CD123 an-
tibodies in phase 2 and phase 1 trials, respectively (51). Small molecule– 
based approaches to control IFN in SLE remain largely unexplored. 
TBK1 inhibition has demonstrated promising results in mice (53), 
but no inhibitor of IFN secretion has yet entered clinical trials. An 
alternative strategy that consists of blocking IFNAR signaling with 
several JAK2 inhibitors is currently evaluated in phase 2 clinical 
studies (51). In this context, we evaluated the effect of chronic IT1t 
intraperitoneal injection in an SLE pristane-induced mouse model. 
Several mouse models have led to a clearer understanding of the 
role of type I IFN in the pathogenesis of lupus-like disease. Pristane- 
induced SLE meets many SLE features including an IFN signature 
and anti-dsDNA and anti-RNA antibodies, and reaches a score of 8 
in the SLE criteria (35). In pristane-induced murine lupus, TLR7 is 
specifically required for the production of RNA-reactive autoanti-
bodies and the development of glomerulonephritis (36). TLR7 defi-
ciency not only abolishes pristane-induced type I IFN production 
but also eliminates autoantibody production and renal disease, in-
dicating a key role of the TLR7/MyD88/type I IFN pathway in this 
model (35, 54, 55). We demonstrate here that IT1t treatment by tar-
geting the TLR7 pathway inhibits the systemic production of IL-1, 
IL-17, and the IFN-induced protein TRAIL similarly to predniso-
lone in pristane-induced SLE mice. Furthermore, IT1t exhibited a 
better reduction of dsDNA antibodies, which serve as a diagnostic 
and prognostic marker, than prednisolone. To sum up, IT1t pro-
vides a new therapeutic alternative to corticosteroids for IFN-triggered 
SLE pathogenesis.
In view of the promising effect of IT1t in healthy donors and the 
SLE mouse model, we tested IT1t on cells isolated from patients 
with lupus. Patients with SLE experience periods of low disease activity 
and also periods of “flares,” where they undergo an inflammatory 
storm (39). Flares are also associated with a massive increase in the 
IFN signature in patients’ blood. To mimic “flares” in vitro, we stimu-
lated patient’s cells with R848. Using pan–IFN- ultrasensitive digital 
ELISA (5), we demonstrate that IT1t treatment controls IFN- secretion 
in activated PBMCs from patients with lupus, acting preferentially 
through diminution of IFN-+ pDCs. In our hands, spontaneous 
secretion of IFN- by frozen PBMCs of adult patients with SLE is 
almost never detectable. However, using digital ELISA, we detected 
IFN secretion on several occasions from fresh ex vivo unstimulated 
cultures of PBMCs from juvenile SLE. We identified four patients 
with clear, albeit distinct, spontaneous inflammatory profiles. For all 
patients’ cells, and irrespective of their specific inflammatory profile, 
IT1t treatment was associated with a reduction of IFN- secretion, 
pSTAT1, and pSTAT3 levels, as well as ISG and cytokine transcription. 
These promising results with patients’ cells, using a small CXCR4 
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agonist with previously unappreciated immunoregulatory properties, 
open new perspectives for the treatment of lupus.
Numerous CXCR4 ligands have been described, including pyri-
dines, quinolones, peptides, or polyazamacrocycle with a large range 
of affinities (56). The excellent control of TLR7-mediated pDCs inflam-
mation by IT1t brings a new level of complexity to CXCR4 signaling 
and associated functions. Initially characterized by crystallography 
in 2010, the IT1t binding site has since been further studied. A 
Fig. 6. IT1t controls induced and spontaneous inflammation in vitro in cells from patients with SLE. (A) PBMCs from healthy controls (HC) and patients with lupus 
(P) were stimulated with R848 to recapitulate disease flares and treated or not with IT1t (20 M). Effect of IT1t was evaluated by IFN- dosage in cell supernatants by 
digital ELISA (Simoa) or by intracellular IFN- expression by flow cytometry. (B) Effect of IT1t on IFN- secretion from TLR7-stimulated cells from patients (P3, P4, P5, and P6) 
was measured by Simoa. Box and whisker plots with median ± SEM showing minimum to maximum. Friedman test with Dunnett post hoc correction. (C) Intracellular IFN- 
expression was assessed by flow cytometry and (D) IFN- was dosed in the supernatant of cells from P1 stimulated with R848 (5 g/ml) and treated with IT1t. (E) Effect of 
IT1t on cells from patients with spontaneous inflammation (SpI) juvenile SLE (JSLE) was evaluated on IFN- production by (F) Simoa in the cell supernatant, by flow cytometry 
to measure pSTAT1 (G and H) and pSTAT3 (I and J), and by RT-qPCR (K) to quantify mRNA levels in PBMCs from four different patients with JSLE. (H and J) Friedman test. 
***P < 0.001, **P < 0.01, *P < 0.05. NS, nonstimulated.
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combination of structure- and ligand-based virtual screening of 
the “IT1t pocket” (57) identified a set of small molecules with ago-
nist or antagonist properties toward CXCL12, demonstrating the 
functionality of this pocket. In a previous study, we demonstrated 
that another thiourea CXCR4 ligand (CB) showed similar biological 
inhibitory properties to IT1t in vivo (19). This highlights the com-
plexity of CXCR4 engagement and validates the IT1t CXCR4 minor 
pocket as a promising pharmacological target for chronic diseases 
in contrast to the CXCR4 major pocket of AMD3100 (20, 23). We 
acknowledge that we have not yet resolved the molecular mecha-
nism linking CXCR4 engagement to TLR7 signaling inhibition. 
Furthermore, we also found that TLR4/TLR8/TLR9 response in pDCs 
and monocytes is also drastically inhibited by IT1t, suggesting a 
broader effect on immune modulation. Thus, understanding the 
molecular pathway will be the next step to fully characterize the role 
of CXCR4 in control of innate immunity. However, we can still 
speculate on some hypothesis. One could be that IT1t binding on 
CXCR4 blocks TLR pathway by affecting the intracellular vesicular 
trafficking (58). This hypothesis can be supported by the observa-
tion that chloroquine, which is known to impair many lysosomal func-
tions, is also a strong inhibitor of IFN production by TLR-stimulated 
pDC and is used in the clinic to treat patients with lupus.
In conclusion, this study demonstrates that the CXCR4 cocrys-
talized ligand IT1t controls TLR7-mediated inflammation in human 
pDCs, controls inflammation and autoantibody formation in mice 
with lupus, and alleviates induced or spontaneous inflammation 
from cells of patients with SLE. Thus, IT1t and, by extension, the 
CXCR4 minor subpocket represent a novel promising axis for ther-
apeutic options in chronic inflammation and autoimmune diseases.
METHODS
Study design
The aim of the study was to evaluate the effect of known antagonists 
(IT1t and AMD3100) of the chemokine receptor CXCR4 on the 
modulation of the innate immune response in pDCs and its potential 
usage as a new therapy in lupus. The sample sizes (healthy donors 
or patients with lupus) for this exploratory study were designed to 
ensure robust statistical results, while adhering to experimental fea-
sibility and minimization of donors. Sample size for mice data was 
designed to maximize statistical power, whereas no randomization 
or blinding was implemented. Details on sampling and experimental 
replicates are provided in each figure legend.
Human samples
The study was approved by the Comité de Protection des Personnes 
(ID-RCB/EUDRACT: 2014-A01017-40) and AC-2014-2289. Inves-
tigations were undertaken with written informed consent.
Blood samples, isolation, and culture of blood leukocytes
The blood from healthy donors was obtained from two sources, either 
from “Etablissement Français du Sang” (convention # 07/CABANEL/ 
106; Paris, France) or from the Apheresis and Blood Donation Unit at 
the Institute of Clinical Transfusion Medicine and Immunogenetics 
(Ulm, Germany), after being approved by the Institutional Review 
Board at Ulm University. For material of patients with lupus, the 
study was approved by the Comité de Protection des Personnes 
(ID-RCB/EUDRACT: 2014-A01017-40 and 2018-A01358-47) in 
France. Experimental procedures with human blood have been ap-
proved by the Necker Hospital Ethical Committees for human re-
search and were done according to the European Union guidelines 
and the Declaration of Helsinki, and informed consent was ob-
tained from all donors (healthy and patients). The clinical data of 
patients with lupus are summarized in table S1. In vitro experi-
ments were performed using human PBMCs isolated by density 
centrifugation from peripheral blood leukocyte separation medium 
(Cambrex, Gaithersburg, MD). Human pDCs were purified by neg-
ative selection with the EasySep Human Plasmacytoid DC enrich-
ment kit (STEMCELL Technologies). After purification, we obtained 
purity higher than 91% for pDCs quantified by flow cytometry. PBMCs 
and pDCs were cultured in RPMI 1640 (Invitrogen, Gaithersburg, MD) 
(R10) containing 10% heat-inactivated fetal bovine serum, penicillin 
(100 U/ml), streptomycin (100 g/ml; 1% pen-strep), and 1 mM glutamine 
(HyClone, Logan, UT). Frozen PBMCs from controls and patients 
with lupus were cultured in RPMI 1640 (Invitrogen, Gaithersburg, 
MD) (R5) containing 5% heat-inactivated human serum AB (Sigma- 
Aldrich, MO, USA). The healthy donors were identified from #1 
to #11 (Figs. 1 to 3) or HC3 to HC6 (Fig. 6) and P1 to P10 for patients 
with SLE and JSLE.
TMCs isolation from tonsils
Collection of tonsils was approved by the Comité de Protection des 
Personnes (ID-RCB/EUDRACT: 2018-A01358-47). Obstructive tonsils 
from healthy children with sleep apnea were removed after a partial 
tonsillectomy. The tissue was kept in phosphate-buffered saline (PBS) 
1× no longer than 2 hours, cut into small pieces, and disrupted using a 
glass pestle onto a 60-mesh steel grid. The TMCs were filtered on a 70-m 
filter and washed in PBS. Ficoll separation was further performed to 
remove the rest of the epithelial tissue and debris. TMCs were cultured 
in R10. The donors were identified from #1 to #7.
CXCR4 knockout experiments
pDCs were seeded at 105 cells/100 l in 96-well plates and incubated 
at 37°C. Cyclophilin B (control) and CXCR4 siRNA (SMARTPool, 
Dharmarcon) were diluted in DOTAP (1,2-dioleoyl-3-trimethylammonium- 
propane; Roche Applied Sciences). The mix was gently mixed and incu-
bated at room temperature for 15 min. After incubation, the mix was 
added to cells in culture at a final concentration of 160 nM. Last, cells were 
incubated at 37°C for 24 hours before adding the stimulation for 16 hours.
Cell stimulation
PBMCs and TMCs were seeded at 2 × 106/ml, and purified pDCs 
were seeded at 5 × 104/100 l. Cells were then stimulated with the 
TLR7/TLR8 agonist Resiquimod (R848; Invivogen) at 5 g/ml or 
inactivated AT-2 HIV-1MN (X4 tropism) and HIV-1ADA (R5 tropism) 
at 60 ng/ml p24CA equivalent [provided by J. D. Lifson (SAIC-NCI, 
Frederick, MD)] or pristane at 200 g/ml (Sigma-Aldrich). Purified 
pDCs were pretreated with the IT1t (Tocris Bioscience) or AMD3100 
(Sigma-Aldrich) at 20 M (or other if specified for 1 hour before 
16 hours of stimulation or as indicated). Cells were then collected 
for RT-qPCR, and supernatants were collected for cytokine detec-
tion. For intracellular IFN- staining, brefeldin A was added to the 
cells at the same time as the stimulus. Cells were then collected and 
stained for flow cytometry analysis.
Cell infection
TZM-bl cells were seeded in flat-bottomed 96-well dishes, cultured 
overnight, and incubated with various concentrations of AMD3100 
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or IT1t for 1 hour before they were infected with virus containing 
20 ng of p24 antigen in a total volume of 100 ml of medium. Three 
days after infection, the cells were lysed, and infection rates were 
determined using the one-step Tropix Gal-Screen Kit as recom-
mended by the manufacturer.
Flow cytometry
Cells were washed in PBS and then incubated with a viability stain 
(Zombie-Aqua, BioLegend) for 30 min at 4°C. After washing, the 
cells were resuspended in PBS containing 2% fetal calf serum and 
2 mM EDTA and stained with the extracellular mix using APC 
(allophycocyanin) anti- BDCA4 (clone 12C2), fluorescein isothiocyanate 
anti-CD123 (clone 6H6), PerCP.cy5.5 anti-CD56 (clone 5.1H11), 
BV421 anti-HLADR (human leukocyte antigen–DR isotype) (clone 
L243), PE.cy7 anti-CD19 (clone 4G7), and APC-cy.7 anti- CD14 
(clone M5E2) all from BioLegend and used at 1:200 and V500 anti- 
CD3 (clone SP34-2, 1:200; BD Bioscience). For IFN- intracellular 
staining, a Fixation/Permeabilization Solution Kit (BD Cytofix/ 
Cytoperm) was used according to the manufacturer’s protocol. Briefly, 
the cells were fixed for 10 min at 4°C with 100 l of the Fixation/
Permeabilization solution and then washed and stained in 100 l of 
the BD Perm/Wash Buffer containing PE (phycoerythrin) anti– 
IFN- (clone REA1013, 1:50; Miltenyi Biotec) antibody for 1 hour at 
4°C. For pIRF7 staining, following the extracellular staining, the 
cells were fixed in 2% paraformaldehyde for 10 min at 4°C and 
then washed and permeabilized with 90% ice-cold methanol for 
20 min at 4°C. The cells were stained with Alexa Fluor 488-IRF7 
pS477/pS479 (K47-671, 1:25; BD Biosciences) and PE anti–IFN- 
antibodies for 1 hour at 4°C. Data acquisition was performed on 
a FACSCanto II flow cytometer using FACSDiva software (BD 
Biosciences, San Jose, CA). FlowJo software (Treestar, Ashland, 
OR) was used to analyze data.
Confocal microscopy
Purified pDCs were pretreated or not with IT1t at 20 M and then 
stimulated with R848 overnight, in the presence of brefeldin A. Cells 
were washed in ice-cold PBS–bovine serum albumin (BSA; 0.2%) 
and then were plated on poly-d-lysine–coated slides and fixed with 
4% paraformaldehyde. Cells were permeabilized with 90% ice-cold 
methanol for 20 min at 4°C and, after washing, were incubated 
with Alexa Fluor 488–IRF7 pS477/pS479 antibody in 0.5% 
saturation buffer PBS-BSA. Last, slides were washed in PBS and 
mounted in Fluoromount-G with DAPI (4′,6-diamidino-2- 
phenylindole) medium (Thermo Fisher Scientific). Images were 
digitally acquired with a Zeiss LSM 710 confocal microscope using 
63× PL APO O.N. 1.4 per oil objective. All analyses were performed 
using the ImageJ software (National Institutes of Health, Bethesda, 
MD, USA). The plugin 3D Viewer was used to create three-dimensional 
images.
All types of IFN detection
To quantify the secretion of functional IFN in TMCs, we used a bio-
logical assay based on a stable cell line where luciferase reporter 
gene is controlled by five IFN-stimulated response elements (STING37 
cell line). First, TMCs supernatants were harvested after 24 hours of 
stimulation and frozen at −20°C for storage. Then, TMCs super-
natants were dispensed in culture wells of a 96-well plate containing 
35 × 103 STING37 cells per well. After 24 hours of culture, luciferase 
activity was determined by adding 50 l of Bright-Glo reagents 
(Promega) to culture wells and measuring bioluminescence with a 
luminometer.
STAT phosphorylation assay
PBMCs were treated or not with IT1t (20 M) overnight. Cells were 
fixed using Beckman Coulter PerFix EXPOSE Fixation Buffer (10 min 
at room temperature) and then permeabilized using Beckman Coulter 
PerFix EXPOSE Permeabilizing Buffer (5 min at 37°C). Cells were 
stained with PE anti-STAT1 pY701 (clone 4a, 1:5; BD Bioscience) 
or Alexa Fluor 488 anti-STAT3 pY705 (clone 4/p-STAT3, 1:5; BD 
Bioscience) and cell surface markers APC-CD3 (clone REA613, 1:30; 
Miltenyi Biotec) and APC–Alexa Fluor 750–CD14 (clone RM052, 
1:30; Beckman Coulter) for 1 hour at room temperature protected 
from light. Flow cytometry analysis was performed on a Gallios 
Beckman Coulter flow cytometer. Results were analyzed using Kaluza 
software v1.3.
Cytokine detection
pDC and tonsil supernatants were tested for multiple cytokine pro-
duction using the bead assay LEGENDplex Antivirus Human panel 
(PBL Assay Science, NJ, USA) according to the manufacturer’s in-
structions.
IFN- in serum and supernatant
As previously reported (5), Simoa digital ELISA specific for IFN- 
was developed using a Quanterix Homebrew Assay, and two auto-
antibodies specific for IFN- were isolated and cloned from two 
APS1/APECED patients (59). The 8H1 antibody clone was used as 
a capture antibody after coating paramagnetic beads (0.3 mg/ml), 
and the 12H5 was biotinylated (biotin/Ab ratio = 30:1) and used as 
the detector. Recombinant IFN-17/I (PBL Assay Science) was used 
as a standard curve after cross-reactivity testing. The limit of detec-
tion was calculated by the mean value of all blank runs ± 3 SDs and 
was 0.23 fg/ml.
RT-qPCR analyses
Total RNA was extracted using the RNeasy Micro kit and was 
submitted to deoxyribonuclease treatment (Qiagen), following the 
manufacturer’s instructions. RNA concentration and purity were 
evaluated by spectrophotometry (NanoDrop 2000c, Thermo Fisher 
Scientific). RNA (500 ng) was reverse-transcribed using the Prime-
Script RT Reagent Kit (Perfect Real Time, Takara Bio) in a 10-l 
reaction. Real-time PCR reactions were performed in duplicate using 
Takyon ROX SYBR MasterMix blue deoxythymidine triphosphate 
(Eurogentec) on an Applied Biosystems QuantStudio 5. Transcripts 
were quantified using the following program: 3 min at 95°C followed 
by 35 cycles of 15 s at 95°C, 20 s at 60°C, and 20 s at 72°C. Values for 
each transcript were normalized to expression levels of RPL13A (60S 
ribosomal protein L13a) using the 2−Ct method. Primers used for 
quantification of transcripts by real time quantitative PCR are indicated 
below:
RPL13A: forward primer, 5′-AACAGCTCATGAGGCTACGG-3′; 
reverse primer, 5′-TGGGTCTTGAGGACCTCTGT-3′
TRAIL: forward primer, 5′-GCTGAAGCAGATGCAGGACAA-3′; 
reverse primer, 5′-TGACGGAGTTGCCACTTGACT-3′
IFN1: forward primer, 5′-CCAGTTCCAGAAGGCTCCAG-3′; 
reverse primer, 5′-TCCTCCTGCATCACACAGGC-3′
IFN4: forward primer, 5′-CCCACAGCCTGGGTAATAGGA-3′; 
reverse primer, 5′-CAGCAGATGAGTCCTCTGTGC-3′
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IFN: forward primer, 5′-TGCTCTCCTGTTGTGCTTCTC-3′; 
reverse primer, 5′-CAAGCCTCCCATTCAATTGCC-3′
IFN1: forward primer, 5′-GGACGCCTTGGAAGAGTCAC-3′; 
reverse primer, 5′-CTGGTCTAGGACGTCCTCCA-3′
IFN2/3: forward primer, 5′-GGGCCTGTATCCAGCCTCAG-3′; 
reverse primer, 5′-GAGGAGGCGGAAGAGGTTGA-3′
IFN: forward primer, 5′-GGCAGCCAACCTAAGCAAGAT-3′; 
reverse primer, 5′-CAGGGTCACCTGACACATTCA-3′
IRF7: forward primer, 5’-CAGATCCAGTCCCAACCAAG-3′; 
reverse primer, 5′-GTCTCTACTGCCCACCCGTA-3′
MxA: forward primer, 5′-AAGCTGATCCGCCTCCACTT-3′; 
reverse primer, 5′-TGCAATGCACCCCTGTATACC-3′
TNF-: forward primer, 5′-GGCGTGGAGCTGAGAGATAAC-3′; 
reverse primer, 5′-GGTGTGGGTGAGGAGCACAT-3′
CXCL10: forward primer, 5′-CGCTGTACCTGCATCAGCAT-3′; 
reverse primer, 5′-GCAATGATCTCAACACGTGGAC-3′
IFN stimulated gene RNA expression in PBMCs from patients 
with lupus
mRNA from treated and nontreated cultured cells were quantified by 
RT-qPCR using TaqMan probes for IFI27 (Hs01086370_m1), IFI44L 
(Hs00199115_m1), ISG15 (Hs00192713_m1), OAS1 (Hs00973637_m1), 
CXCL10 (Hs01124251_m1), TNFa (Hs01113624_g1), IL-6 (Hs00985639_
m1), and IL-17 (Hs00174383_m1); the relative abundance of each 
target transcript was normalized to the expression level of HPRT1 
(Hs03929096_g1) and assessed with the Applied Biosystems StepOne 
Software v2.1.
Computational details
An initial structure for AMD3100 was obtained from the ZINC15 database 
(60). The receptor structure was obtained from PDB (Protein Data Bank) 
ID: 3ODU (chain A) (20). The program LeDock (61) was used for 
docking. A cubic box with 40 Å of edge, containing the whole extra-
cellular extreme of the CXCR4 receptor, was used to perform the initial 
docking screening. We conducted 50 runs of docking simulations, 
keeping the final pose in each of them. Subsequently, the 50 resulting 
poses are clustered with a root mean square deviation cutoff of 1 Å. 
The clusters are ordered according to the binding energy values given 
by the program force field. The best pose was selected from the most 
populated cluster among the top 10 scored ones. This structure was 
further optimized with a simulated annealing procedure. The simula-
tions were performed with NAMD 2.12 (62), using the CHARMM36m 
force field (63). Parameters and topologies for the ligands were ob-
tained from SwissParam (64). The complexes were placed in a box of 
explicit solvent with 15 Å of padding in the three dimensions around 
the complex structures. The model TIP3P was used for the water molecules 
(65). Counter ions were added for neutralization in each system. Long-
range electrostatics were evaluated using the PME (particle mesh 
Ewald) method (66). The solvent was initially equilibrated to the box 
dimensions along 150 ps of NVT simulation at 300 K with the complex 
structure fixed in its initial geometry. Next, 1 ns of NPT simulation 
was performed with harmonic constraints on the protein and ligand’s 
atoms. Langevin dynamics (67) was used to control the temperature 
and pressure of the system at 300 K and 1 atm, respectively. Then, a 
local optimization was performed with short cycles of a simulated an-
nealing (SA) procedure. The SA protocol was composed of five cycles, 
involving a heating ramp between 300 and 350 K for 1 ns, then a cooling 
ramp back to 300 K for 1 ns, and, afterward, 1 ns of re- equilibration at 
300 K. In total, the protocol involved 15 ns of optimization. The last 
step involved the equilibration at 300 K. The receptor’s backbone was 
kept fixed during the simulation using a harmonic restraint. Side chains, 
ligand, and solvent were allowed to move freely.
In vivo treatment of mice
Animal experiments were performed blindly by Washington Bio-
technology, Inc. The animals were housed in a temperature- and 
humidity-controlled room with 12-hour light/dark cycles with food 
and water ad libitum. The Washington Biotechnology, Inc. Animal 
Care and Use Committee reviewed and approved all mouse experi-
ments (IACUC no. 17-006). Animal welfare and experimental proto-
cols strictly complied with the Guide for the Care and Use of Laboratory 
Animals and the ethics and regulations. For pristane injection, each 
mouse in all groups was intraperitoneally injected with 0.5 ml of 
pristane (cat no. P9622, Sigma-Aldrich, BioReagent). Prednisolone 
(4.5 mg; P4153, Sigma-Aldrich) was dissolved in 3 ml of PBS to 
prepare a solution (1.5 mg/ml). All mice in group 2 were treated daily 
with prednisolone (15 mg/ml oral gavage). IT1t was dissolved in PBS 
and intraperitoneally injected daily at 3 mg/kg (mpK), 10, or 30 mpK 
(groups 3 to 5). ELISA was performed using the following kit according 
to the manufacturer’s recommendation: TNF- ELISA kit (cat no. 
MTA00B, R&D Systems), IL-1 ELISA kit (cat no. MLB00C, R&D 
Systems), IL-17 ELISA kit (cat no. M1700, R&D Systems), TRAIL ELISA 
kit (cat. no. ELM-TRAIL-1, RayBiotech), and dsDNA (IgM) ELISA 
Kit (cat. no. 5120, Alpha Diagnostic). For histology, formalin- 
fixed samples of each kidney from mice were received by HistoTox 
Labs and processed routinely. One slide per block was sectioned and 
stained with hematoxylin and eosin. Glass slides were evaluated by 
a board-certified veterinary pathologist, using light microscopy. 
Glomerulonephritis was characterized by slight thickening of mesangial 
matrix or mesangial hypercellularity (>3 nuclei per segment).
Nanostring gene expression analysis
Total RNA was extracted from isolated pDCs of controls and pa-
tients and was diluted with ribonuclease-free water at 20 ng/l, and 
100 ng (5 l) of each sample was analyzed using the Human Immu-
nology kit v2 and Nanostring Counter. Each sample was analyzed 
in a separate multiplexed reaction including, in each, eight negative 
probes and six serial concentrations of positive control probes. Data 
were imported into nSolver analysis software (version 2.5) for quality 
checking and normalization of data according to NanoString anal-
ysis guidelines, using positive probes and housekeeping genes. For 
analysis, mRNA expression levels were log-transformed and mean- 
centered per donor (when applicable) before hierarchical clustering 
(Qlucore Omics Explorer version 3.1). Up-regulated genes from the 
heat map shown in Fig. 2B were classified with respect to their 
known link to IFN signaling or functional promoter. Identification of 
ISGs was made using the database from Shaw et al. (68) (http://isg.data.
cvr.ac.uk/). Promoters of the remaining genes were identified on 
the basis of the “Molecular Signatures Database v6.2” C3 from the 
Broad Institute (http://software.broadinstitute.org/gsea/msigdb/ 
index.jsp) (69, 70). When multiple transcription factors were iden-
tified for the same gene, the one in common with other genes was 
chosen in priority for the graphical representation.
Statistical analysis
Cellular data are shown as median and min/max. Datasets were analyzed 
by Kruskal-Wallis test with Dunn’s post hoc correction. Univariate 
distributions of flow cytometry data were performed by probability 
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binning in 300 bins using FlowJo software. Animal data are shown 
as mean ± SEM. Datasets were analyzed using two-way analysis of 
variance (ANOVA) with Bonferroni post hoc comparison (cyto-
kine concentration in time course). GraphPad Prism 5 (GraphPad 
Software, San Diego, CA) was used for data analysis and prepara-
tion of all graphs. P values less than 0.05 were considered to be sta-
tistically significant.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/7/eaav9019/DC1
Fig. S1. AMD3100 and IT1t bind to CXCR4 and are not toxic.
Fig. S2. IT1t controls TLR7-mediated inflammation in HIV-stimulated pDCs.
Fig. S3. IT1t inhibits pDC activation through CXCR4 engagement.
Fig. S4. Genes from the R848 stimulated group are significantly enrich in ISG.
Table S1. Clinical information of recruited patients.
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